Purinergic Antagonist Suramin Aggravates Myocarditis and Increases Mortality by Enhancing Parasitism, Inflammation, and Reactive Tissue Damage in Trypanosoma cruzi-Infected Mice

Table 1

Parasitological parameters and mortality in mice infected with T. cruzi and treated with different doses of the nonselective purinergic antagonist suramin.

Groups	Prepatent period (days)	MP (parasites ×10^3/0.1 mL blood)	PP (parasites ×10^3/0.1 mL blood)	Mortality (n/%)
SAL	ND	ND	ND	0/0%
INF	5	27.11 ± 15.08	49.17 ± 20.15	5/35.7%
SR5	5	29.16 ± 11.31	53.55 ± 20.37	5/35.7%
SR10	4	45.71 ± 10.94	80.13 ± 48.52	7/50%
SR20	4	58.83 ± 15.40†	117.25 ± 60.0†	9/64.3%

Data are reported as mean ± standard deviation. MP, mean parasitemia; ND, not detected; PP, peak of parasitemia; SAL, control noninfected (0.9% NaCl solution); INF, untreated infected; SR5, 10, and 20; groups treated with suramin at 5, 10, or 20 mg/kg, respectively. †Statistical difference (), compared to INF and † compared to INF and SR5; Kruskal-Wallis test.